Esperienze

Corsello A, Milani GP, Picca M, Buzzetti R, Carrozzo R, Gambino M, Chiaffoni G, Marchisio P, Mameli C. Recurrent upper respiratory tract infections in early childhood: a newly defined clinical condition. Italian Journal of Pediatrics, 2024;:-

Leggi

Benatti SV, Venturelli S, Buzzetti R, Binda F, Belotti L, Soavi L, Biffi AM, Spada MS, Casati M, Rizzi M and on behalf of the SURVIVING COVID study group. Socio-economic conditions affect health-related quality of life, during recovery from acute SARS-CoV-2 infection Results from the VASCO study (VAriabili Socioeconomiche e COVID-19), on the “Surviving-COVID” cohort, from Bergamo (Italy). BMC Infectious Diseases , 2024 24:815;:-

Spada E, Gagliardi L, Buzzetti R. La differenza c’è? Si vede?. Quaderni ACP, 2024;31 (6):261-262

Buzzetti R, Cirilli N, Raia V, Salvatore D, Daniele A. CFDB – WWW.CFDB.EU - FAQ. Orizzonti FC, 2024;20 (2):34-36

Buzzetti R, Cirilli N, Raia V, Salvatore D, Daniele A. DAL CYSTIC FIBROSIS DATABASE (CFDB): Sono utili i bifosfonati per il trattamento dell’osteopenia/osteoporosi in età pediatrica?. Orizzonti FC, 2024;20 (1):27-29

Buzzetti R, Gagliardi L. Il sesso femminile espone il neonato con fibrosi cistica a un esito peggiore? Un processo in tre atti. Quaderni ACP, 2024;31(3):105-107

Calderazzo MA, Buzzetti R, Daccò V. EFFECTS OF LUMACAFTOR/IVACAFTOR ON CYSTIC FIBROSIS DISEASE PROGRESSION IN CHILDREN 2 THROUGH 5 YEARS OF AGE HOMOZYGOUS FOR F508DEL-CFTR: A PHASE 2 PLACEBO-CONTROLLED CLINICAL TRIAL. Orizzonti FC, 2024;20 (2):27-30

Calderazzo MA, Buzzetti R, Lucidi V. IMPACT OF 1-YEAR SUPPLEMENTATION WITH HIGH-RICH DOCOSAHEXAENOID ACID (DHA) ON CLINICAL VARIABLES AND INFLAMMATORY BIOMARKERS IN PEDIATRIC CYSTIC FIBROSIS: A RANDOMIZED DOUBLE-BLIND CONTROLLED TRIAL. Orizzonti FC, 2024;20 (2):31-33

Nazzari E, Buzzetti R, Graziano S. Conoscere ed interpretare le differenze –ELEXACAFTOR/TEZACAFTOR/IVACAFTOR TREATMENT AND DEPRESSION-RELATED EVENTS. Orizzonti FC, 2024;20 (1):24-26